Abstracts tagged "autoantibodies and autoantigens"

Abstract Number: 2932 • 2016 ACR/ARHP Annual Meeting
HLA-DR3 Restricted Response to Lupus-Related Auto-Antigen Smd: Autoreactive T Cells Are Inherent in Normal Immune Repertoires
Zhenhuan Zhao¹, Jiling Ren¹, Chao Dai², Carol Kannapell¹, Qian Wang³, Felicia Gaskin⁴ and Shu Man Fu⁵, ¹Medicine/CIIR/Rheumatology, University of Virginia, Charlottesville, VA, ²Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, VA, ³University of Virginia, Charlottesville, VA, ⁴Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, ⁵Department of Medicine, University of Virginia, Charlottesville, VA
Background/Purpose: HLA class II is the major susceptibility region for systemic lupus erythematosus (SLE) and other autoimmune disorders such as rheumatoid arthritis, multiple sclerosis and…
Abstract Number: 608 • 2014 ACR/ARHP Annual Meeting
Identification of Novel Autoantibodies in Patients with Ankylosing Spondylitis Using Human Protein Microarray
Matthew Presby¹, Mark J. Soloski¹, John A. Flynn², Clifton O. Bingham III¹, Michael M. Ward³ and Grant H. Louie⁴, ¹Johns Hopkins University, Baltimore, MD, ²Dept of Medicine, Johns Hopkins University, Baltimore, MD, ³Bldg 10 CRC Rm 4-1339, NIAMS/NIH, Bethesda, MD, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Ankylosing spondylitis (AS) is an immune-mediated disease for which the search for autoantibodies has been elusive. Conventional immunoserological approaches are slow and limited…
Abstract Number: 2522 • 2013 ACR/ARHP Annual Meeting
Novel Autoantibody Against CAF-1 Is a Biomarker For CNS Manifestation in patients With SLE
Kentaro Doe¹, Kazuhisa Nozawa², Kaori Hiruma², Yusuke Yamada¹, Yuko Matsuki¹, Soichiro Nakano¹, Michihiro Ogasawara³ and Yoshinari Takasaki⁴, ¹Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of internal medicine and rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Proliferating cell nuclear antigen (PCNA) is known to be an autoantigen specifically recognized by antibodies in sera from patients with systemic lupus erythematosus (SLE). Although a prevalence of anti-PCNA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].